Data-Driven Discovery of Molecular Targets for Antibody-Drug Conjugates in Cancer Treatment

Figure 4

Experimental validation of the protein expression for (a) NECTIN4 and (b) ERBB2, as two FDA-approved antibody-drug conjugate targets, in representative samples of urothelial cell carcinoma.